المؤلفون: Perera, Lalith¹ (AUTHOR) lalith.perera@nih.gov, Brown, Shalyn M.^2,3 (AUTHOR) shalyn.brown@nih.gov, Silver, Brian B.² (AUTHOR) brian.silver@nih.gov, Tokar, Erik J.² (AUTHOR) erik.tokar@nih.gov, Sinha, Birandra K.² (AUTHOR) sinha1@niehs.nih.gov

المصدر: International Journal of Molecular Sciences. Jan2025, Vol. 26 Issue 2, p635. 15p.

مصطلحات موضوعية: *CYTOTOXINS, *DOXORUBICIN, *MULTIDRUG resistance, *DRUG resistance, *TOPOTECAN

المؤلفون: Limin Tao¹, Min Xiu¹, Juanjuan Qian¹, Qiuyue Wang¹ ndyfy01824@ncu.edu.cn, Hongling Zou¹, Yanfeng Gong²

المصدر: European Journal of Gynaecological Oncology. Dec2024, Vol. 45 Issue 6, p157-163. 7p.

مصطلحات موضوعية: *DOXORUBICIN, *OVARIAN cancer, *GLYCOLYSIS, *DRUG resistance in cancer cells, *CANCER chemotherapy

المؤلفون: Paulsen, Torbjørn¹ tpa@ous-hf.no, Birgisdottir, Alda^1,2, Myklebust, Tor Åge^2,3, Dørum, Anne¹, Zahl Eriksson, Ane Gerda^1,4, Vilming, Bente¹

المصدر: European Journal of Gynaecological Oncology. Dec2024, Vol. 45 Issue 6, p32-39. 8p.

مصطلحات موضوعية: *TRABECTEDIN, *DOXORUBICIN, *CISPLATIN, *DESENSITIZATION (Psychotherapy), OVARIAN cancer patients

المؤلفون: Mohmaed Ali, Ma Ida^1,2 (AUTHOR) m.mohmaed@nki.nl, Nijstad, A. Laura³ (AUTHOR), Boosman, René J.^1,2 (AUTHOR), Crombag, Marie-Rose B. S.³ (AUTHOR), Barnett, Shelby⁴ (AUTHOR), Veal, Gareth J.⁴ (AUTHOR), Lalmohamed, Arief^5,6 (AUTHOR), van Erp, Nielka P.⁷ (AUTHOR), Steeghs, Neeltje⁸ (AUTHOR), Zwaan, C. Michel^9,10 (AUTHOR), Beijnen, Jos H.^1,2,6 (AUTHOR), Siebinga, Hinke^1,2 (AUTHOR), Huitema, Alwin D. R.^1,2,5,11 (AUTHOR)

المصدر: Clinical Pharmacokinetics. Dec2024, Vol. 63 Issue 12, p1711-1722. 12p.

مصطلحات موضوعية: *DOXORUBICIN, *PHARMACOKINETICS, *INFANTS, *DATA modeling, *AGE, *AGE groups

المؤلفون: Lin, Zhihui¹ (AUTHOR), Wu, Chang¹ (AUTHOR), Song, Dongyan¹ (AUTHOR), Zhu, Chenxi¹ (AUTHOR), Wu, Bosen¹ (AUTHOR), Wang, Jie² (AUTHOR) jiewang1991@foxmail.com, Xue, Yangjing¹ (AUTHOR) yangjingxue@wmu.edu.cn

المصدر: Redox Report. Dec2024, Vol. 29 Issue 1, p1-12. 12p.

مصطلحات موضوعية: *WESTERN immunoblotting, *DOXORUBICIN, *CARDIOTOXICITY, *LABORATORY mice, *ANTINEOPLASTIC agents, *CELLULAR signal transduction

المؤلفون: Sorroza-Martínez, Kendra¹ (AUTHOR) ksorroza@correo.xoc.uam.mx, González-Sánchez, Ignacio² (AUTHOR) igonzalez@quimica.unam.mx, Villamil-Ramos, Raúl³ (AUTHOR) raul.villamil@uaem.mx, Cerbón, Marco² (AUTHOR) macer@unam.mx, Guerrero-Álvarez, Jorge Antonio³ (AUTHOR) jguerrero@uaem.mx, Coronel-Cruz, Cristina⁴ (AUTHOR) cristina.coronel.c@gmail.com, Rivera, Ernesto⁵ (AUTHOR) riverage@unam.mx, González-Méndez, Israel³ (AUTHOR) riverage@unam.mx

المصدر: Pharmaceutics. Dec2024, Vol. 16 Issue 12, p1509. 15p.

مصطلحات موضوعية: *ALTERNATIVE treatment for cancer, *DOXORUBICIN, *SCANNING electron microscopy, *INCLUSION compounds, *ANTINEOPLASTIC agents, *CYTOTOXINS

المصدر: A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Gounder M, Schoffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 Nov;21(11):1423-1432. doi: 10.1016/S1470-2045(20)30451-4. Epub 2020 Oct 6.

Other URLs: http://vivli.org/members/ourmembers/

المصدر: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

Other URLs: https://grants.nih.gov/policy/sharing.htm

المؤلفون: GOG Foundation

المصدر: A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Mori KM, Giuliano PD, Lopez KL, King MM, Bohart R, Goldstein BH. Pronounced clinical response following the oncolytic vaccinia virus GL-ONC1 and chemotherapy in a heavily pretreated ovarian cancer patient. Anticancer Drugs. 2019 Nov;30(10):1064-1066. doi: 10.1097/CAD.0000000000000836.
Manyam M, Stephens AJ, Kennard JA, LeBlanc J, Ahmad S, Kendrick JE, Holloway RW. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2021 Dec;163(3):481-489. doi: 10.1016/j.ygyno.2021.10.069. Epub 2021 Oct 20. Erratum In: Gynecol Oncol. 2022 May;165(2):401. doi: 10.1016/j.ygyno.2022.02.014.
Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, Fitzsimmons CK, Kennard JA, King M, LeBlanc J, Lopez K, Manyam M, McKenzie ND, Mori KM, Stephens AJ, Sarfraz A. 2020 International Gynecologic Cancer Society, Oral Plenary Session presentation of VIRO-15 Phase 2 Trial Data, Robert Holloway, AdventHealth Cancer Institute, Orlando, FL. International Journal of Gynecologic Cancer 2020;30:A9-A10
Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, LeBlanc J, McKenzie ND, Mori KM, Ahmad S. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. JAMA Oncol. 2023 Jul 1;9(7):903-908. doi: 10.1001/jamaoncol.2023.1007.

المؤلفون: Seagen Inc., Pfizer

المصدر: Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer

المصدر: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

المصدر: A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements
Brem EA, Li H, Beaven AW, Caimi PF, Cerchietti L, Alizadeh AA, Olin R, Henry NL, Dillon H, Little RF, Laubach C, LeBlanc M, Friedberg JW, Smith SM. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. J Geriatr Oncol. 2022 Mar;13(2):258-264. doi: 10.1016/j.jgo.2021.10.003. Epub 2021 Oct 20.

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: A Phase 1 Trial of Pomalidomide in Combination With Liposomal Doxorubicin in Patients With Advanced or Refractory Kaposi Sarcoma

المصدر: A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

Other URLs: https://grants.nih.gov/policy/sharing.htm

المصدر: EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer
Konstantinopoulos PA, Gonzalez-Martin A, Cruz FM, Friedlander M, Glasspool R, Lorusso D, Marth C, Monk BJ, Kim JW, Hinson P, Ajipa O, Pretre V, Han Y, Matulonis UA. EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). Future Oncol. 2022 Oct;18(31):3481-3492. doi: 10.2217/fon-2022-0666. Epub 2022 Sep 6.

المؤلفون: National Cancer Institute (NCI)

المصدر: A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings